SG/CALL/NOVO-NORDISK B/1150/0.1/20.06.25 | Market Closed - Boerse Frankfurt Warrants 03:47:42 2024-06-28 pm EDT | ||
| 1.13 EUR | -7.38% |
|
| Current month | +28.89% | ||
| 1 month | +26.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 1.16 | -4.92% |
| 24-06-27 | 1.22 | -0.81% |
| 24-06-26 | 1.23 | -6.11% |
| 24-06-25 | 1.31 | +15.93% |
| 24-06-24 | 1.13 | -5.83% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 03:47 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9CVV |
| ISIN | DE000SU9CVV2 |
| Date issued | 2024-02-14 |
| Strike | 1,150 kr |
| Maturity | 2025-06-20 (356 Days) |
| Parity | 10 : 1 |
| Emission price | 0.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.39 € |
|---|---|
| Lowest since issue | 0.71 € |
| Spread | 0.03 € |
| Spread % | 2.56% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
